<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612388</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00926; ch18Reuthebuch3</org_study_id>
    <nct_id>NCT03612388</nct_id>
  </id_info>
  <brief_title>Combined Use of a Novel Cardioplegic Formula With Myocardial Protection System (MPS)® Versus Cardioplexol ® in Isolated Coronary Artery Bypass Grafting (CABG) Using MiECC;</brief_title>
  <acronym>MiECC</acronym>
  <official_title>Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Isolated CABG Using MiECC (Minimal Extracorporeal Circulation System)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus
      Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG
      (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2010</start_date>
  <completion_date type="Actual">March 13, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lab values for cardial biomarkers</measure>
    <time_frame>perioperative during hospital stay for CABG</time_frame>
    <description>cardial biomarkers measured are high sensitive troponin T (hs-TrT), Creatinkinase, (CK) Creatinkinase myocardial type (CK-MB)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>30 days after CABG</time_frame>
    <description>death after coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for intensive care unit</measure>
    <time_frame>perioperative during hospital stay for CABG</time_frame>
    <description>duration of stay at intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dysrhythmia</measure>
    <time_frame>perioperative during hospital stay for CABG</time_frame>
    <description>rhythm disturbance after coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>perioperative during hospital stay for CABG</time_frame>
    <description>bleeding complication after coronary artery bypass grafting</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">211</enrollment>
  <condition>Complication of Extracorporeal Circulation</condition>
  <condition>Complication of Coronary Artery Bypass Graft</condition>
  <arm_group>
    <arm_group_label>cardioplegia with MPS® (Myocardial protection system)</arm_group_label>
    <description>cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cardioplegia with Cardioplexol ®</arm_group_label>
    <description>cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation</intervention_name>
    <description>use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).</description>
    <arm_group_label>cardioplegia with MPS® (Myocardial protection system)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing isolated CABG (coronary artery bypass grafting) using MiECC (Minimal
        extracorporeal circulation system) at the department of cardial surgery University Hospital
        Basel Switzerland
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CABG using MPS® or Cardioplexol ®

        Exclusion Criteria:

          -  use of other colloid solution than Cardioplexol ® or MPS®

          -  other inventions than CABG

          -  myocardial infarction &lt;7 days before CABG

          -  patients denial of data use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Reuthebuch, PD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, CH-4031 Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Herzchirurgie, Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

